Antibody Technologies and Platforms 2

• 4393 · PDF Development of an anti-CD171 (L1CAM) antibody-drug conjugate with high avidity and strong activity in resistant tumor models Kyoung-Ho Pyo, Hee Su Chae, Seong-Hyun Park, Younggeun Lee, Hojin Yeom, Sowon Aum, Sun Hee Park, Huijo Oh, Cheyeon Kim, Mi Jin Yoo, Min-Jung Shin, Hyo Jeong Hong, Jong-Soo Kang, Ju Hwan Kim, Seon-Joo Yoon, Taedong Han
• 4395 · PDF A best-in-class HER2xHER2 novel biparatopic antibody-drug conjugate with an efficacious, low-toxicity design that maximizes antibody functionality Ge Song, Yushi Chi, Xiansong Xiong, Rui Liu, Xiaoling Yuan, Wan-Jen Yang, Wanli Zhang, Xinwei Wang, Boqi Gu, Qian Zou, Peng Huang, Kuichao Qu, Haixiang Yu, Futang Yang, Qingyu Wang, Chen Hu, Jijun Yuan
• 4396 · PDF Selective intratumoral distribution and post-T-DXd activity of K-679, an ultra-high-DAR EGFR-targeted antibody drug-loaded unimicelle conjugate (ADUC) Hideo Yoshida, Hideyuki Higashi, Masato Mori, Kahori Hosono, Nobuhiro Fujimaki
• 4397 · PDF Leveraging patient-derived organoids to investigate bystander effects of antibody-drug conjugates in solid tumor backgrounds Oksana Sirenko, Nikki Carter
• 4398 · PDF Developing 3D cell models for high-throughput antibody-drug conjugate screening in cancer Peilin Tian, Morgan Hamon, Sean Porazinski, Maria Kavallaris, Kristopher A. Kilian, Justin Gooding
• 4399 · PDF ANT045: A novel format, antibody fragment drug-conjugate (FDC) product for challenging cMET-expressing solid tumors Mahendra Deonarain, Bryan Edwards, Gokhan Yahioglu, Isabel Perez-Castro, Sam Ness, Anja Pomowski, Laura Bouché, Soraya Diez-Posada, Lowri Davies, Howard Desmond
• 4400 · PDF Degrader antibody conjugates (DACs) as a next-generation therapeutic approach for selective and potent targeted protein degradation in EGFR-positive cancers Jihye Lee, Soohyun Lee, Jiyoung Kim, Han Wool Kim, So Hyuk Kim, Onnuri Bae, Jeonghwa Han, Je Ho Ryu, Song Hee Lee
• 4401 · PDF A novel antibody-drug conjugate targeting alkaline phosphatases ALPP and ALPPL2 in solid tumors Yujun Huang, Xiao Liang, Yajuan Xue
• 4402 · PDF EGFR and LGR5 dual-targeting antibody-drug conjugate-based therapeutic strategies for the improved treatment of colorectal cancer Peyton C. High, Zhengdong Liang, Maya Cappellino, Tiffani Blackburn, Cara Guernsey-Biddle, Shraddha Subramanian, Yueh-Ming Shyu, Adela Aldana, Yukimatsu Toh, Kendra S. Carmon
• 4403 · PDF A fast and robust development process providing new highly internalized anti-hHER2 antibody-drug conjugates Eric Chabrol, Marie-Claire Phélipot, Cécile Lemoigne, Julie Lichière, Nadjiba Marès, Alice Aymard, Alexandre Bagnolini, Sophie Mesnard, Caroline Huber, Matthieu Tassa, Ester Morgado, Jacques Fieschi
• 4404 4404 Diverse VHH antibodies targeting multiple LGR5 epitopes for cancer therapy Chenrui Xu, Yifan Li, Trang Nguyen, Roger Shek, Longfei Chong, Tek H. Lee, Yuxiang Lang, Li Yi, Per Greisen
• 4405 · PDF Real-time, label-free assessment of HER2-targeted antibody-drug conjugate therapies Danny Flanigan, BEN STREETER, STACIE CHVATAL, DANIEL MILLARD
• 4406 · PDF Mouse analog of micvotabart pelidotin, an antibody-drug conjugate targeting extradomain-B of fibronectin, demonstrates anti-tumor efficacy in an immunotherapy-refractory syngeneic head and neck squamous cell carcinoma model Anthony B. Rodriguez, Amanda Facklam, Justin Trickett, Sara Lewandowski, Matthew Iovino, Chuan Shen, Frank Wang, Nicolas Severe, Marsha Crochiere
• 4407 · PDF Integrative design of PSM101 Lock-antibody for EGFR-positive tumors through clinical protease profiling and structure-based computer simulation Yi-An Cheng, Yun-Chi Lu, Yu-Chi Lee, Chen-Yung Hung
• 4409 · PDF Comparing potential bispecific formats comprising of trastuzumab and a humanized OKT3 Sabrina Mateos, Catherine Bladen, Abbie Hardisty, Emily Blackwood, Holly Guz, Stacey Walker, Stephen Anderson, Michael Fiebig
• 4410 · PDF The discovery and development of a bispecific T cell engager prodrug targeting ENPP3 Li Chen, Lindi Wang, Yingyu Li, Xin Wang, Yang Xin, Mingzhu Shao, Jiangtao Ning, Ziyu Chen, Cheng Luo, Jingjing Nie, Yue Wu, Tingting Yang, Hai Huang, Miaomiao Song, Yu Liang
• 4411 · PDF Discovery of mutation-independent cKit degrading bispecific antibodies that suppress tumor growth in preclinical models of GIST Kenneth Ng, Shruti Yadav, Brianna McIntosh, Andy Goodrich, Hai Tran, Josef Gramespacher, Kimberly Hoi, Sara Yan, Brian Hiller, Adison McLaggan, Zhong Huang, Noah Solomon, John Coan, Jon Sitrin, Shyra Gardai, Ken Flanagan
• 4412 · PDF Discovery and characterization of GI-128: A PD-L1 x LILRB1/2/4 bispecific antibody as a macrophage engager Seong Hun Kim, Eunji Ahn, Min Sang Yoon, Ji Cheol Kim, Hye Jun Park, Wonjae Lee, Hyuckjun Mok, Eun Jin Lee, Jisoo Kim, Young Min Oh, Kook Hwan Kim, Myoung Ho Jang
• 4413 · PDF KRAS amplification creates a targetable pMHC antigen for T cell engager therapy to overcome KRAS inhibitor resistance Lorenzo Maso, Diamond N. Mensah, Angelina Pizzo, Sergio A. Rodriguez-Aponte, Samantha Sze, Weifeng Liu, Sean T. Toenjes, Paul Da Silva Jardine, Christoph Rader, Lauren E. Stopfer
• 4414 · PDF A bispecific antibody-drug conjugate targeting protein tyrosine kinase 7 and fibroblast activation protein alpha simultaneously acts on tumor cells and the tumor microenvironment Yifan Zhan, Shi Chen, Jingen Xu, Xiaofang Chen, Changping Zheng, Xianfei Pan, Shaojie Wang, Simin Xia, Haijia Yu, Yujie Feng, Guoyuan Peng, Huifeng Jia, Xiaopei Cui, Xiangyang Zhu
• 4415 · PDF AI-powered analysis of millions of IHC images identifies 19 spatially highly co-expressed protein pairs to enable bispecific antibody development Sukjun Kim, Hosik Kim, Biagio Brattoli, Sergio Pereira, Siraj Mahamed Ali
• 4416 · PDF Overcoming the limited monospecific target landscape in cancer via discovery of tumor selective AND and OR gate bispecifics Daniel Holdbrook, Katherine Vousden, Michael Hunter, Roy Pettipher, Mark Edwards
• 4417 · PDF GS24-B025, a novel CDH17- and CEA-directed bispecific antibody-drug conjugate, for the treatment of colorectal cancer Zeng Qi, Fu Li, Liping Shao, Yuting Lu, Chong Ding, Nan Li, Huan Wang, Weiming He, Qiangqiang Deng, Peng Qi, Wenqiang Zhai, Yihui Lin, Xiaozhen Wang, Fanglong Yang, Siqin Wang, Lei Jin, John L. Xu
• 4418 · PDF Preclinical characterization of a potential best-in-class camptothecin-based antibody-drug conjugate targeting ADAM metallopeptidase domain 9 Rui Liu, Lan Ding, Yushi Chi, Ge Song, Kuichao Qu, Wan-jen Yang, Kun Yan, Jinbo Liu, Huixin Yan, Xiaoling Yuan, Ying Chen, Zhenjian Li, Chen Hu, Jijun Yuan
• 4419 · PDF Development of a first-in-class camptothecin-based antibody-drug conjugate targeting ALPP/ALPPL2 with potent antitumor activity and excellent tolerability Rui Liu, Lingli Zhang, Fan Yang, Junjie Zhang, Wan-Jen Yang, Xiaoling Yuan, Jichen Sha, Yushi Chi, Ge Song, Weiguang Qu, Zhiliang Lv, Qian Zou, Huixin Yan, Chen Hu, Jijun Yuan

在会议检索中浏览本分会场